Skip to main content

Table 1 Survival at 4 years follow-up for burden of copy number alteration quartile sub-groups (Kaplan-Meier estimates)

From: Accumulation of copy number alterations and clinical progression across advanced prostate cancer

Clinical trial endpoint Estimated survival (%)
Copy number alteration burden (Quartile) Q1 Q2 Q3 Q4
Failure-free survival 63 36 29 31
Progression-free survival 77 50 40 43
Metastatic progression-free survival 82 57 45 43
Prostate cancer-specific survival 88 67 61 52
Overall survival 83 64 48 48
  1. Legend: range of copy number burdens (%) included in quartiles: (Q1: less than 10.55; Q2: 10.55–18.06; Q3: 18.06–27.03; Q4: 27.03–75.45)